What is ENDRA Life Sciences Earnings Yield (Joel Greenblatt) %?
ENDRA Life Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $19.59 Mil.
ENDRA Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.52 Mil. ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -53.76%.
The historical rank and industry rank for ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
NDRA'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -48720.43 Med: -34.9 Max: 8532.96
Current: -909.09
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of ENDRA Life Sciences was 8532.96%. The lowest was -48720.43%. And the median was -34.90%.
NDRA's Earnings Yield (Joel Greenblatt) % is ranked worse than 99.13% of 231
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.28
vs NDRA: -909.09
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ENDRA Life Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
ENDRA Life Sciences Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
ENDRA Life Sciences Earnings Yield (Joel Greenblatt) % Chart
Competitive Comparison of ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) %
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % falls into.
ENDRA Life Sciences Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
ENDRA Life Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
ENDRA Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.52 Mil.
ENDRA Life Sciences (NAS:NDRA) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
ENDRA Life Sciences Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRA has been successfully added to your 